antibodies (TTG) should be performed in patients with a diagnosis of lymphocytic duodenosis (LD), which may herald CD. The main objectives of this study were to determine the indications and histological findings for duodenal biopsies in a teaching hospital setting, and the prevalence of LD and new diagnoses of CD in this cohort.

**Methods** 1043 patients with duodenal biopsies taken during upper gastrointestinal endoscopy in a teaching hospital setting in 24 months (2009–11) were studied retrospectively. Demographics, indications and histological findings were documented. Patients with known CD were excluded from the study; if an individual had more than one biopsy in the time period then only the first biopsy was included. When a specific abnormality was targeted for biopsy this was recorded. For LD patients, TTG results were recorded where available.

**Results** The patients’ median age was 60 (range 16–97); 55% were female. Anemia was the commonest indication for biopsy (in 51% of patients) followed by weight loss and abdominal pain.

76% of biopsies were normal. LD was found in 155 patients (15%), of whom 64% were female. Biopsy appearances of CD with positive TTG were found in 15 patients (1.2%). Documentation of serology was not always available and so the incidence of CD in this population may be underestimated. Crohn’s disease was diagnosed in 3 biopsies (0.29%). Graft versus host disease, drug effect, lymphangiectasia and infection were seen (1 Giardia, 1 atypical mycobacteria, 1 Strongyloides).

70 duodenal biopsies (7%) targeted specific abnormalities, including 6 malignancies (3 adenocarcinoma, 1 carcinoid tumour and 1 lymphoma) and 6 benign polyps including 2 adenomas. Of the 973 non-targeted biopsies, 772 (79%) were normal.

There were no statistical differences between positive biopsy results and specific indications.

**Conclusion** Whilst the majority of biopsies were normal, significant abnormalities were found in 24% and LD was present in 15%.

While important for the diagnosis of CD, duodenal biopsy was also vital for the diagnosis other pathologies including infection, Crohn’s disease, drug effect and tumours.

**Disclosure of Interest** None Declared.

---

**PTh-184** PUSH ENTEROSCOPY LEADS TO A CHANGE IN DIAGNOSIS IN THE MAJORITY OF PATIENTS WITH POSITIVE COELIAC SEROLOGY AND NEGATIVE DUODENAL BIOPSY

doi:10.1136/gutjnl-2013-304907.671

1R Willington, 2Lashmar, 3Benes, 4Barrett, 5S Weaver, 6McCudden, 7Smith, 8C Gordon, 9CC Cilicitera, 10McLaughlin. 1AMU, Southampton General Hospital, Southhampton; 2Department of Gastroenterology; 3Department of Pathology, Royal Bournemouth Hospital, Bournemouth; 4Department of Gastroenterology, Southampton General Hospital, Southhampton; 5Department of Gastroenterology, St Thomas’ Hospital; 6Diabetes and Nutritional Sciences Division, King’s College London, London, UK

**Introduction** Coeliac disease is associated with significant morbidity, and is an underdiagnosed condition with an estimated prevalence of 1% in the UK population. Current British Society of Gastroenterology Guidelines classify individuals with positive coeliac serology and negative duodenal biopsy to latent coeliac disease and do not recommend further investigation or the initiation of a gluten free diet.

In our recent practice patients at our institution with a strong clinical suspicion of coeliac disease and negative duodenal biopsies following a gluten containing diet undergo a push enteroscopy with biopsies of the jejunum and duodenum and histological reassessment of the original duodenal biopsies before a diagnosis of latent coeliac disease is made.

We aimed to investigate whether push enteroscopy and histological reassessment increased the diagnostic yield of coeliac disease.

**Methods** We searched our prospective endoscopy database for all patients with positive EMA or TTG results but negative D2 biopsies, who had undergone enteroscopy for a possible diagnosis of coeliac disease since 2007. Data including serology, result of histological reassessment of duodenal biopsies and assessment of jejunal biopsies were recorded.

**Results** 13 patients were identified; 4 (31%) were male, the median age was 45 (range 19–78). In all 13, EMA testing had been performed, of which 9 were positive (69%). In 9, TTG results were available, of which 9 were positive (100%). Following review of the original duodenal biopsies by a second pathologist, 7 (54%) of the 13 patients were re-classified to active coeliac disease; median Marsh grade of 1 (range 0–2).

Of the remaining 6 patients, 5 (83%) had evidence of active coeliac disease on jejunal biopsy; median Marsh grade of 2 (range 0–3b).

Review of the jejunal biopsies alone, without review of original duodenal biopsies, would have led to active coeliac disease being diagnosed in 12 (92%) of 13 patients.

**Conclusion** In this small retrospective series of patients with positive coeliac serology and negative duodenal biopsies, repeat histological assessment and jejunal biopsy led to a change in diagnosis in 92% of patients. These findings are unlikely to be limited to our institution. Our findings support the recommendation that a diagnosis of latent coeliac disease should only be made following repeat histological assessment and enteroscopy with jejunal biopsy.

**Disclosure of Interest** None Declared.

---

**PTh-185** CAPSULE ENDOCOSPY AND OBSCURE GASTROINTESTINAL BLEEDING: EXPERIENCE FROM A TERTIARY CENTRE

doi:10.1136/gutjnl-2013-304907.672

1P S Sidhu, 1K Drew, 1M E McAlindon, 1R Sidhu. Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK

**Introduction** Capsule endoscopy (CE) is the first line modality to investigate the small bowel (SB) in patients with obscure gastrointestinal bleeding (OGB). We investigated the largest cohort of patients to date with OGB who underwent CE.

**Methods** All patients referred for CE for OGB were included retrospectively. Data was collected for demographics, clinical indication (overt bleeding (OB) or iron deficiency anaemia (IDA)) the presence of co-morbidity; medications including anticoagulation, diagnostic yield (DY) and subsequent follow up.

**Results** A total of 1324 patients were identified. The mean age was 60 years with females consisting of 55%. The indication for CE was IDA in 75%(n=971) and OB in 27%. Significant co-morbidities were present in 35% of patients. Whilst 8% of patients were on warfarin, 6%(n=84) were transfusion dependent. The cumulative number of lesions identified was 1086. The overall DY was 36%(n=473) for lesions deemed to be the source of OGB. On logistic regression, increasing age (p < 0.001) and transfusion dependence (p = 0.02) were associated with a DY with CE. The commonest diagnosis was angioectasia (AE) in 23%(n=302). Other SB findings included ulcers and erosions in 25%(n=326), fresh blood without a definite source in 6%(n=79) whilst tumours, polyps and crohns disease represented 2% each respectively. Miscellaneous findings in the SB included diverticulae (14), SB strictures (15), SB varices (9), dielaufoy (1) and others (23).

There was no significant difference in the DY between those with IDA and OB (p = 0.35) and between the sexes (p = 0.44). Management was altered in 78%(n=367) of those with a positive DY, in the form of further procedures (42%, n = 155). Of these, 35%(n=53) had double balloon enteroscopy, 24%(n=36) had push enteroscopy, 25%(n=35) had repeat standard endoscopy, 17 patients were referred for surgery whilst 2 patients had intraoperative enteroscopy. 34%(n=52) of patients received argon
photocoagulation therapy for their AE. On logistic regression, factors associated with a subsequent change in management included the indication of OB ($p = 0.03$), the presence of comorbidity ($p = 0.03$), transfusion dependence ($p = 0.02$) and the presence of AE ($p < 0.001$) on the CE. In 14% of patients, significant lesions were found outside the SB (upper GI tract 12% and colon 2%).

Conclusion This is the largest series on the use of CE in OGB in the published literature. A significant number of patients with a positive DY had a change in management. Factors that were more likely to predict an alteration of outcome were the presence of co-morbidity, transfusion dependence and the presence of AE. Although, the DY did not differ significantly between those with IDA and OB, management was more likely to be altered in those with OB.

Disclosure of Interest None Declared.

**PTH-186** THE UTILITY OF CAPSULE ENDOSCOPY IN PATIENTS WITH IRON DEFICIENCY ANAEMIA UNDER 50 YEARS - IS THE JUICE WORTH THE SQUEEZE?

doi:10.1136/gutjnl-2013-304907.673

1 S Sidhu, 1M E McAlindon, 1K Drew, 1R Sidhu. Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK

Introduction The role of capsule endoscopy (CE) in patients with iron deficiency anaemia (IDA) under the age of 50 years remains unclear. There is paucity of data on its use in this age group. The aim of this study was to assess the utility of CE in patients under the age of 50 years in comparison to the older cohort.

Methods All patients referred for CE routinely for IDA were included. Patients were divided into group 1 ($\leq 50$ years) and group 2 ($>50$ years). Data was collected retrospectively for demographics, the presence of co-morbidity, medications including anticoagulation, diagnostic yield and subsequent follow up. The data was analysed using SPSS Ver 18.

Results There were 971 patients with IDA identified with 28% of patients belonging to group 1. The mean age was 40 years in this group (range 17–49 years) with 61% (n = 168) of the cohort being female. The diagnostic yield in group 1 was 28% (n = 76) with no difference between the sexes. Significant diagnoses were found in this age group including erosions and ulcers 26% (n = 71), small bowel (SB) angioectasia (AE) in 10% (n = 27), SB tumours (7), cohn’s disease (7), SB bowel strictures (3), and SB varices (2). Other findings (14) included endometriosis, a dielaufoy lesion, diverticulum and fresh blood from uncertain site. On logistic regression, the presence of diabetes ($p = 0.02$) and the use of warfarin ($p = 0.049$) was associated with increased yield. Management was altered in 59% (n = 57) of patients with a positive yield on CE. This was in the form of double balloon enteroscopy (11), push enteroscopy (2), repeat OGD (2), surgery (2), repeat CE (5) with only one patient receiving argon photocoagulation therapy in this group. On logistic regression, clinical factors that were associated with a management change included the presence of rheumatology disease ($p = 0.006$), diabetes ($p = 0.014$), previous transfusion ($p = 0.01$) and SB AE ($p = 0.002$) in group 1. The diagnostic yield in group 2 was 38% which was significantly higher than in group 1 ($p = 0.02$). Whilst small bowel tumours were equally common in both groups, angioectasia was commoner in group 2 ($p < 0.001$).

Conclusion A significant proportion of patients below 50 years are referred for CE. Although the diagnostic yield is lower compared to those above 50 years, significant pathology is found in this age group. CE should be considered in the management pathway of patients under 50 years with recurrent IDA in both sexes.

Disclosure of Interest None Declared.

**PTH-187** A NOVEL NON-INVASIVE APPROACH TO DIAGNOSE BILE ACID DIARRHOEA (BAD) USING AN ELECTRONIC NOSE (E-NOSE) AND FIELD ASYMMETRIC ION MOBILITY SPECTROSCOPY (FAIMS)

doi:10.1136/gutjnl-2013-304907.674

1 J Covington, 1E Westinbrink, 1M Thomas, N O’Connell, C Bailey, C Nwokolo, 1J Cullis, N Williams, K Bardhan, 1R Arasaradnam. School of Engineering, 1University of Warwick; 1University Hospital Coventry & Warwickshire, Coventry, UK; 2Nuclear Medicine, University Hospital Coventry & Warwickshire, Coventry; 2Rotherham NHS Foundation Trust, Rotherham; 3Clinical Sciences Research Institute, University of Warwick, Coventry, UK

Introduction A third of diarrhoea predominant irritable bowel syndrome (D-IBS) results from bile acid malabsorption (BAM); diagnosed by $^{35}$SeHCAT retention test. We have previously demonstrated the ability of using an E-nose and FAIMS to detect inflammatory bowel disease (IBD) by shifts in the patterns of volatile organic compounds (VOCs) in the gases and vapours that emanate from urine samples. Here, we have extended our work to detect BAM from urine odours alone.

Methods Technology Principles - E-nose This uses an array of gas phase chemical sensors which are broadly tuned to different chemical groups. When a urine sample is presented to the sensor array, a unique response is produced. By taking all of the sensor responses together, a bio-odorant fingerprint is created. FAIMS operates on similar principles, but produces its fingerprint by measuring the differences in mobility of ionised chemicals in high electric fields.

Subjects and patients BAM (7 day retention value of $< 15$%): n = 15. Controls: ulcerative colitis in remission (SCAI score of $< 4$): n = 20; healthy subjects: n = 7. Urine was collected in 10 ml aliquots and stored frozen in universal containers. For assay, the containers were first heated to 60 ± 1°C. The headspace (the air above the sample) was then pumped from the containers and analysed by an AlphaMOS FOX 4000 E-nose and FAIMS instrument. Discriminant Function Analysis and Fisher Discriminant Analysis (FDA) were used for statistical evaluation, respectively.

Results The FOX 4000 E-nose plot (Figure 1) shows separate and distinct groupings of patients with BAM, UC, and healthy controls. FAIMS analysis gave a broadly similar pattern (not shown).

Abstract PTH-187 Figure 1

Conclusion D-IBS related to BAM is a common condition and treatment with BA sequestrants is effective in the majority. The SeHCAT retention test makes diagnosis easy but is not available in all centres: our pilot data offers an alternative diagnostic approach with high potential.

Disclosure of Interest None Declared.